Pharmacogenetics of Parkinson’s Disease – Through Mechanisms of Drug Actions

Author(s): Marek Drozdzik, Monika Bialecka, Mateusz Kurzawski

Journal Name: Current Genomics

Volume 14 , Issue 8 , 2013

Become EABM
Become Reviewer
Call for Editor


In the last years due to development of molecular methods a substantial progress in understanding of genetic associations with drug effects in many clinical disciplines has been observed. The efforts to define the role of genetic polymorphisms in optimizing pharmacotherapy of Parkinson’s disease (PD) were also undertaken. So far, some promising genetic loci for PD treatment were determined. In the review pharmacogenetic aspects of levodopa, dopamine agonists and COMT inhibitors are discussed.

Keywords: Parkinson's disease, Pharmacogenetics, Genetic polymorphism.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 06 February, 2014
Page: [568 - 577]
Pages: 10
DOI: 10.2174/1389202914666131210212521
Price: $65

Article Metrics

PDF: 15